Skip to main content

01.12.2015 | Men’s Health (R Carrion and C Yang, Section Editors)

The Challenge of Erectile Dysfunction Management in the Young Man

Erschienen in: Current Urology Reports | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Erectile dysfunction (ED) in a young man is an important health problem that significantly impacts the patient’s quality of life and can have a detrimental effect on his well-being and relationship with his partner. Erectile dysfunction or impotence is one of the few disorders that will bring a young man into the doctor’s office. This review article focuses on the epidemiology, etiology, presentation, work-up, and treatment of young men (age ~20–40 years old) presenting with complaints of ED. It is important to identify the precise etiology of the ED before proceeding with further evaluation and treatment because the work-up can be invasive and costly. ED is estimated to affect 20 % of men above 40 years of age, with the incidence increasing with increasing age. Erectile dysfunction has traditionally been seen as an age-dependent problem; however, approximately 2 % of men are affected at 40 years of age but this may be a gross underestimation secondary to reporting bias. Because ED is traditionally seen in the aging male population, studies regarding ED tend to be more frequently carried out among middle-aged and elderly men rather than in young men. These studies underline how comorbidities such as diabetes mellitus, cardiovascular or neurological pathologies, and medication use are strongly linked with ED. In addition, ED has been described to be associated with obesity or physical inactivity. This review article summarizes the important information that all sexual medicine providers should be familiar with when diagnosing, counseling, and treating young men with erectile dysfunction.
Literatur
1.
Zurück zum Zitat N.C.C. Impotence. NIH consensus development panel on impotence. JAMA. 1993;270:83–90.CrossRef N.C.C. Impotence. NIH consensus development panel on impotence. JAMA. 1993;270:83–90.CrossRef
2.
Zurück zum Zitat Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang J-h. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 2007;4:57–65.CrossRefPubMed Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang J-h. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 2007;4:57–65.CrossRefPubMed
4.
Zurück zum Zitat Zimmet PA, Albert KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.CrossRefPubMed Zimmet PA, Albert KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.CrossRefPubMed
5.
Zurück zum Zitat Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151:54–61.PubMed Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151:54–61.PubMed
7.
Zurück zum Zitat Prieto D. Physiological regulation of penile arteries and veins. Int J Impot Res. 2007;20:17–29.CrossRefPubMed Prieto D. Physiological regulation of penile arteries and veins. Int J Impot Res. 2007;20:17–29.CrossRefPubMed
8.
Zurück zum Zitat Williams SK, Melman A. Novel therapeutic targets for erectile dysfunction. Maturitas. 2012;71(1):20–7.CrossRefPubMed Williams SK, Melman A. Novel therapeutic targets for erectile dysfunction. Maturitas. 2012;71(1):20–7.CrossRefPubMed
9.
Zurück zum Zitat Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.CrossRefPubMed Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.CrossRefPubMed
10.
Zurück zum Zitat Rosen RC et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–26.CrossRefPubMed Rosen RC et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–26.CrossRefPubMed
11.
Zurück zum Zitat Rajkumar RP. The impact of disrupted childhood attachment on the presentation of psychogenic erectile dysfunction: an exploratory study. J Sex Med. 2015;12:798–803.CrossRefPubMed Rajkumar RP. The impact of disrupted childhood attachment on the presentation of psychogenic erectile dysfunction: an exploratory study. J Sex Med. 2015;12:798–803.CrossRefPubMed
13.
Zurück zum Zitat Sachs BD. The false organic-psychogenic distinction and related problems in the classification of erectile dysfunction. Int J Impot Res. 2003;15(1):72–8.CrossRefPubMed Sachs BD. The false organic-psychogenic distinction and related problems in the classification of erectile dysfunction. Int J Impot Res. 2003;15(1):72–8.CrossRefPubMed
14.
Zurück zum Zitat Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: perspectives from affective neuroscience. Annu Rev Psychol. 2002;53:545–74.CrossRefPubMed Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: perspectives from affective neuroscience. Annu Rev Psychol. 2002;53:545–74.CrossRefPubMed
15.
Zurück zum Zitat Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry. 1999;60 Suppl 22:12–7.PubMed Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry. 1999;60 Suppl 22:12–7.PubMed
16.
Zurück zum Zitat Nutt DJ, Glue P, Lawson C. The neurochemistry of anxiety: an update. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:737–52.CrossRefPubMed Nutt DJ, Glue P, Lawson C. The neurochemistry of anxiety: an update. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:737–52.CrossRefPubMed
17.
Zurück zum Zitat Rosen R, Porst H, Montorsi F. The premature ejaculation prevalence and attitudes (PEPA) survey: a multi- national survey. 11th World Congress of the International Society of Sexual and Impotence Research, October 17–21. Rosen R, Porst H, Montorsi F. The premature ejaculation prevalence and attitudes (PEPA) survey: a multi- national survey. 11th World Congress of the International Society of Sexual and Impotence Research, October 17–21.
18.
Zurück zum Zitat Broderick GA, Arger P. Duplex Doppler ultrasonography: noninvasive assessment of penile anatomy and function. Semin Roentgenol. 1993;28:43–56.CrossRefPubMed Broderick GA, Arger P. Duplex Doppler ultrasonography: noninvasive assessment of penile anatomy and function. Semin Roentgenol. 1993;28:43–56.CrossRefPubMed
19.••
Zurück zum Zitat Yang Y, Hu JL, Ma Y, et al. Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection? Int J Impot Res. 2012;24(5):191–5.CrossRefPubMed Yang Y, Hu JL, Ma Y, et al. Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection? Int J Impot Res. 2012;24(5):191–5.CrossRefPubMed
20.
Zurück zum Zitat Lue TF, Hricak H, Marich KW, Tanagho EA. Vasculogenic impotence evaluated by high-resolution ultrasonography and pulsed Doppler spectrum analysis. Radiology. 1985;155:777–81.CrossRefPubMed Lue TF, Hricak H, Marich KW, Tanagho EA. Vasculogenic impotence evaluated by high-resolution ultrasonography and pulsed Doppler spectrum analysis. Radiology. 1985;155:777–81.CrossRefPubMed
21.
Zurück zum Zitat Wasserman MD, Pollak CP, Spielman AJ, Weitzman ED. The differential diagnosis of impotence. The measurement of nocturnal penile tumescence. JAMA. 1980;243(20):2038–42.CrossRefPubMed Wasserman MD, Pollak CP, Spielman AJ, Weitzman ED. The differential diagnosis of impotence. The measurement of nocturnal penile tumescence. JAMA. 1980;243(20):2038–42.CrossRefPubMed
22.
Zurück zum Zitat Kessler WO. Nocturnal penile tumescence. Urol Clin N Am. 1988;15(1):81–6. Jun;12(3):373–80. Kessler WO. Nocturnal penile tumescence. Urol Clin N Am. 1988;15(1):81–6. Jun;12(3):373–80.
23.
Zurück zum Zitat Karacan I, Scott FB, Salis PJ, Attia SL, Ware JC, Altinel A, et al. Nocturnal erections, differential diagnosis of impotence, and diabetes. Biol Psychiatry. 1977;12(3):373–80.PubMed Karacan I, Scott FB, Salis PJ, Attia SL, Ware JC, Altinel A, et al. Nocturnal erections, differential diagnosis of impotence, and diabetes. Biol Psychiatry. 1977;12(3):373–80.PubMed
24.
Zurück zum Zitat Licht MR, Lewis RW, Wollan PC, Harris CD. Comparison of RigiScan and sleep laboratory nocturnal penile tumescence in the diagnosis of organic impotence. J Urol. 1995;154:1740–3.CrossRefPubMed Licht MR, Lewis RW, Wollan PC, Harris CD. Comparison of RigiScan and sleep laboratory nocturnal penile tumescence in the diagnosis of organic impotence. J Urol. 1995;154:1740–3.CrossRefPubMed
25.
Zurück zum Zitat Levine AL, Lenting L. Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Urol Clin N Am. 1995;22:775–88. Levine AL, Lenting L. Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Urol Clin N Am. 1995;22:775–88.
26.
Zurück zum Zitat Helgason AR, Arver S, Adolfson I, Dickman P, Granath F, Steineck G. ‘Potency’: the validation of information from a self-administered questionnaire using objective measurements of night-time erections and test-retest reliability. Br J Urol. 1998;81:135–41.CrossRefPubMed Helgason AR, Arver S, Adolfson I, Dickman P, Granath F, Steineck G. ‘Potency’: the validation of information from a self-administered questionnaire using objective measurements of night-time erections and test-retest reliability. Br J Urol. 1998;81:135–41.CrossRefPubMed
27.
Zurück zum Zitat Karacan I, Williams RL, Thornby JI, Salis PJ. Sleep related penile tumescence as a function of age. Am J Psychiatry. 1975;132:932–7.CrossRefPubMed Karacan I, Williams RL, Thornby JI, Salis PJ. Sleep related penile tumescence as a function of age. Am J Psychiatry. 1975;132:932–7.CrossRefPubMed
28.
Zurück zum Zitat Cilurzo P, Canale D, Turchi P, Giorgi PM, Menchini Fabris GF. The RigiScan system in the diagnosis of male sexual impotence. Arch Ital Urol Androl. 1992;64 Suppl 2:81–5. Cilurzo P, Canale D, Turchi P, Giorgi PM, Menchini Fabris GF. The RigiScan system in the diagnosis of male sexual impotence. Arch Ital Urol Androl. 1992;64 Suppl 2:81–5.
29.
Zurück zum Zitat Puyau FA, Lewis RW. Corpus cavernosography. Pressure flow and radiography. Investig Radiol. 1983;18(6):517–22.CrossRef Puyau FA, Lewis RW. Corpus cavernosography. Pressure flow and radiography. Investig Radiol. 1983;18(6):517–22.CrossRef
30.
Zurück zum Zitat Rudnick J, Bödecker R, Weidner W. Significance of the intracavernosal pharmacological injection test, pharmacocavernosography, artificial erection and cavernosometry in the diagnosis of venous leakage. Urol Int. 1991;46(4):338–43.CrossRefPubMed Rudnick J, Bödecker R, Weidner W. Significance of the intracavernosal pharmacological injection test, pharmacocavernosography, artificial erection and cavernosometry in the diagnosis of venous leakage. Urol Int. 1991;46(4):338–43.CrossRefPubMed
31.
Zurück zum Zitat Shabsigh R, Fishman IJ, Toombs BD, Skolkin M. Venous leaks: anatomical and physiological observations. J Urol. 1991;146(5):1260–5.PubMed Shabsigh R, Fishman IJ, Toombs BD, Skolkin M. Venous leaks: anatomical and physiological observations. J Urol. 1991;146(5):1260–5.PubMed
32.
Zurück zum Zitat Motiwala HG, Patel DD, Joshi SP, Baxi HM, Desai KD, Shah KN. Experience with penile venous surgery. Urol Int. 1993;51(1):9–14.CrossRefPubMed Motiwala HG, Patel DD, Joshi SP, Baxi HM, Desai KD, Shah KN. Experience with penile venous surgery. Urol Int. 1993;51(1):9–14.CrossRefPubMed
33.
Zurück zum Zitat Dorsey P, Keel C, Klavens M, Helstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2010;11:1109–22.CrossRefPubMed Dorsey P, Keel C, Klavens M, Helstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2010;11:1109–22.CrossRefPubMed
34.•
Zurück zum Zitat Barnett ZL, Robleda-Gomez S, Pachana NA. Viagra: the little blue pill with big repercussions. Aging Ment Health. 2012;16(1):84–8.CrossRefPubMed Barnett ZL, Robleda-Gomez S, Pachana NA. Viagra: the little blue pill with big repercussions. Aging Ment Health. 2012;16(1):84–8.CrossRefPubMed
35.••
Zurück zum Zitat Goldstein I, McCullough AR, Jones LA, Hellstrom WJ, Bowden CH, Didonato K, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9(4):1122–33.CrossRefPubMed Goldstein I, McCullough AR, Jones LA, Hellstrom WJ, Bowden CH, Didonato K, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9(4):1122–33.CrossRefPubMed
36.
Zurück zum Zitat Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2010;19(11):1427–37.CrossRefPubMed Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2010;19(11):1427–37.CrossRefPubMed
37.
Zurück zum Zitat Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96(12B):29M–31M. Epub 2005 Jul 21. Review.CrossRefPubMed Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96(12B):29M–31M. Epub 2005 Jul 21. Review.CrossRefPubMed
38.
Zurück zum Zitat Cheitlin MD, Hutter Jr AM, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;33:273–82.CrossRefPubMed Cheitlin MD, Hutter Jr AM, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;33:273–82.CrossRefPubMed
39.
Zurück zum Zitat Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005;96(3):257–80. Review.CrossRefPubMed Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005;96(3):257–80. Review.CrossRefPubMed
40.
Zurück zum Zitat Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50:351–9.CrossRefPubMed Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50:351–9.CrossRefPubMed
41.
Zurück zum Zitat Ströberg P, Hedelin H, Ljunggren C. Treatment of erectile dysfunction with PDE-5 inhibitors. Difficult for the physician to choose between the preparations—the patient should be given the opportunity to try out all three. Lakartidningen. 2006;103(14):1107–8. 1110–1.PubMed Ströberg P, Hedelin H, Ljunggren C. Treatment of erectile dysfunction with PDE-5 inhibitors. Difficult for the physician to choose between the preparations—the patient should be given the opportunity to try out all three. Lakartidningen. 2006;103(14):1107–8. 1110–1.PubMed
42.
Zurück zum Zitat Ljunggren C, Hedelin H, Salomonsson K, Ströberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med. 2007;5(2):469–75.CrossRefPubMed Ljunggren C, Hedelin H, Salomonsson K, Ströberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med. 2007;5(2):469–75.CrossRefPubMed
43.•
Zurück zum Zitat Carvalheira AA, Pereira NM, Maroco J, Forjaz V. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med. 2012;9:2361–9.CrossRefPubMed Carvalheira AA, Pereira NM, Maroco J, Forjaz V. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med. 2012;9:2361–9.CrossRefPubMed
44.
Zurück zum Zitat Palmer MJ, Bell AS, Fox DN, Brown DG. Design of second generation phosphodiesterase 5 inhibitors. Curr Top Med Chem. 2007;7(4):405–19. Review.CrossRefPubMed Palmer MJ, Bell AS, Fox DN, Brown DG. Design of second generation phosphodiesterase 5 inhibitors. Curr Top Med Chem. 2007;7(4):405–19. Review.CrossRefPubMed
45.
Zurück zum Zitat van Ahlen H, Peskar BA, Sticht G, Hertfelder HJ. Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J Urol. 1994;151(5):1227–30.PubMed van Ahlen H, Peskar BA, Sticht G, Hertfelder HJ. Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J Urol. 1994;151(5):1227–30.PubMed
46.
Zurück zum Zitat Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol. 1987;137:829–36.PubMed Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol. 1987;137:829–36.PubMed
47.
Zurück zum Zitat Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol. 1985;133(1):39–41.PubMed Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol. 1985;133(1):39–41.PubMed
48.
Zurück zum Zitat Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol. 1991;146(6):1564–5.PubMed Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol. 1991;146(6):1564–5.PubMed
49.
Zurück zum Zitat Floth A, Schramek P. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone. J Urol. 1991;145(1):56–9.PubMed Floth A, Schramek P. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone. J Urol. 1991;145(1):56–9.PubMed
50.
Zurück zum Zitat Linet OI, Neff LL. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Investig. 1994;72(2):139–49.CrossRefPubMed Linet OI, Neff LL. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Investig. 1994;72(2):139–49.CrossRefPubMed
51.
Zurück zum Zitat Aboseif SR, Wetterauer U, Breza J, Benard F, Bosch R, Stief CG, et al. The effect of venous incompetence and arterial insufficiency on erectile function: an animal model. J Urol. 1990;144(3):790–3.PubMed Aboseif SR, Wetterauer U, Breza J, Benard F, Bosch R, Stief CG, et al. The effect of venous incompetence and arterial insufficiency on erectile function: an animal model. J Urol. 1990;144(3):790–3.PubMed
52.
Zurück zum Zitat Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin N Am. 1995;22(4):833–45. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin N Am. 1995;22(4):833–45.
53.
Zurück zum Zitat Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334(14):873–7.CrossRefPubMed Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334(14):873–7.CrossRefPubMed
54.
Zurück zum Zitat Michal V, Kramar R, Pospıchal J, Hejhal L. Direct arterial anastomosis on corpora cavernosa penis in the therapy of erective impotence. Rozhl Chir. 1973;52:587–90. Czech.PubMed Michal V, Kramar R, Pospıchal J, Hejhal L. Direct arterial anastomosis on corpora cavernosa penis in the therapy of erective impotence. Rozhl Chir. 1973;52:587–90. Czech.PubMed
55.
Zurück zum Zitat Michal V, Kramar R, Pospıchal J. Femoro-pudendal by-pass, internal iliac thromboendarterectomy and direct arterial anastomosis to the cavernous body in the treatment of erectile impotence. Bull Soc Int Chir. 1974;33:343–50.PubMed Michal V, Kramar R, Pospıchal J. Femoro-pudendal by-pass, internal iliac thromboendarterectomy and direct arterial anastomosis to the cavernous body in the treatment of erectile impotence. Bull Soc Int Chir. 1974;33:343–50.PubMed
56.
57.
Zurück zum Zitat Kayıgil O, Okulu E, Aldemir M, Onen E. Penile revascularization in vasculogenic erectile dysfunction (ED): long-term follow-up. BJU Int. 2011;109:109–15.CrossRefPubMed Kayıgil O, Okulu E, Aldemir M, Onen E. Penile revascularization in vasculogenic erectile dysfunction (ED): long-term follow-up. BJU Int. 2011;109:109–15.CrossRefPubMed
58.
Zurück zum Zitat Sarramon JP, Malavaud B, Braud F, Bertrand N, Vaessen C, et al. Evaluation of male sexual function by the International Index of Erectile Function after deep dorsal vein arterialization of the penis. J Urol. 2001;166:576–80.CrossRefPubMed Sarramon JP, Malavaud B, Braud F, Bertrand N, Vaessen C, et al. Evaluation of male sexual function by the International Index of Erectile Function after deep dorsal vein arterialization of the penis. J Urol. 2001;166:576–80.CrossRefPubMed
59.
Zurück zum Zitat Munarriz R, Mulhall J, Goldstein I. Glenn’s Urologic Surgery. 6th ed, 2004, pgs. 573–581 Munarriz R, Mulhall J, Goldstein I. Glenn’s Urologic Surgery. 6th ed, 2004, pgs. 573–581
60.
Zurück zum Zitat Basar MM, Aydin G, Mert HC, Keles I, Caglayan O, Orkun S, et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology. 2005;66(3):597–601.CrossRefPubMed Basar MM, Aydin G, Mert HC, Keles I, Caglayan O, Orkun S, et al. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology. 2005;66(3):597–601.CrossRefPubMed
61.
Zurück zum Zitat Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–14.CrossRefPubMed Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–14.CrossRefPubMed
62.
Zurück zum Zitat Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10(1):245–84.CrossRefPubMed Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10(1):245–84.CrossRefPubMed
63.
Zurück zum Zitat Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36.CrossRefPubMed Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36.CrossRefPubMed
64.
Zurück zum Zitat Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.PubMedCentralCrossRefPubMed Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.PubMedCentralCrossRefPubMed
65.
Zurück zum Zitat Yoshimura N, Kato R, Chancellor MB, Nelson JB, Glorioso JC. Gene therapy as a future treatment for erectile dysfunction. Expert Opin Biol Ther. 2010;10:1305–14.PubMedCentralCrossRefPubMed Yoshimura N, Kato R, Chancellor MB, Nelson JB, Glorioso JC. Gene therapy as a future treatment for erectile dysfunction. Expert Opin Biol Ther. 2010;10:1305–14.PubMedCentralCrossRefPubMed
66.••
Zurück zum Zitat Lin CS, Xin Z, Dai J, Huang Y-C, Lue TF. Stem-cell therapy for erectile dysfunction. Expert Opin Biol Ther. 2013;13:1585–97.CrossRefPubMed Lin CS, Xin Z, Dai J, Huang Y-C, Lue TF. Stem-cell therapy for erectile dysfunction. Expert Opin Biol Ther. 2013;13:1585–97.CrossRefPubMed
67.
Zurück zum Zitat Morrison SJ, Shah NM, Anderson DJ. Regulatory mechanisms in stem cell biology. Cell. 1997;88:287–98.CrossRefPubMed Morrison SJ, Shah NM, Anderson DJ. Regulatory mechanisms in stem cell biology. Cell. 1997;88:287–98.CrossRefPubMed
68.
Zurück zum Zitat Lin C-S, Xin Z-C, Deng C-H, Ning H, Lin G, Lue TF. Recent advances in andrology-related stem cell research. Asian J Androl. 2008;10:171–5.CrossRefPubMed Lin C-S, Xin Z-C, Deng C-H, Ning H, Lin G, Lue TF. Recent advances in andrology-related stem cell research. Asian J Androl. 2008;10:171–5.CrossRefPubMed
69.
Zurück zum Zitat Bochinski D, Lin GT, Nunes L, Carrion R, Rahman N, Lin CS, et al. The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU Int. 2004;94:904–9.CrossRefPubMed Bochinski D, Lin GT, Nunes L, Carrion R, Rahman N, Lin CS, et al. The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU Int. 2004;94:904–9.CrossRefPubMed
70.
Zurück zum Zitat Bahk Y, Jung JH, Han H, Min SK, Lee YS. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant. 2010;8:150–60.PubMed Bahk Y, Jung JH, Han H, Min SK, Lee YS. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant. 2010;8:150–60.PubMed
71.
Zurück zum Zitat Qiu X, Fandel TM, Ferretti L, Albersen M, Zhang H, Lin G, et al. Both immediate and delayed intracavernous injection of autologous adipose-derived stromal vascular fraction enhances recovery of erectile function in a rat model of cavernous nerve injury. Eur Urol. 2012;62:720–7.PubMedCentralCrossRefPubMed Qiu X, Fandel TM, Ferretti L, Albersen M, Zhang H, Lin G, et al. Both immediate and delayed intracavernous injection of autologous adipose-derived stromal vascular fraction enhances recovery of erectile function in a rat model of cavernous nerve injury. Eur Urol. 2012;62:720–7.PubMedCentralCrossRefPubMed
72.
Zurück zum Zitat Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol. 2005;47:80–6.CrossRefPubMed Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol. 2005;47:80–6.CrossRefPubMed
73.
Zurück zum Zitat Laumann EO, Waite LJ. Sexual dysfunction among older adults: prevalence and risk factors from a nationally representative U.S. probability sample of men and women 57–85 years of age. J Sex Med. 2008;5:2300–11.PubMedCentralPubMed Laumann EO, Waite LJ. Sexual dysfunction among older adults: prevalence and risk factors from a nationally representative U.S. probability sample of men and women 57–85 years of age. J Sex Med. 2008;5:2300–11.PubMedCentralPubMed
74.
Zurück zum Zitat Bajos N, Wellings K, Laborde C, Moreau C. Sexuality and obesity, a gender perspective: results from French national random probability survey of sexual behaviours. BMJ. 2010;340:2573.CrossRef Bajos N, Wellings K, Laborde C, Moreau C. Sexuality and obesity, a gender perspective: results from French national random probability survey of sexual behaviours. BMJ. 2010;340:2573.CrossRef
75.
Zurück zum Zitat Janiszewski PM, Janssen I, Ross R. Abdominal obesity and physical inactivity are associated with erectile dysfunction independent of body mass index. J Sex Med. 2009;6:1990–8.CrossRefPubMed Janiszewski PM, Janssen I, Ross R. Abdominal obesity and physical inactivity are associated with erectile dysfunction independent of body mass index. J Sex Med. 2009;6:1990–8.CrossRefPubMed
Metadaten
Titel
The Challenge of Erectile Dysfunction Management in the Young Man
Publikationsdatum
01.12.2015
Erschienen in
Current Urology Reports / Ausgabe 12/2015
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-015-0553-3

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.